Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[What is the best sequence of treatment for patients with EGFR mutations?].

Revue de pneumologie clinique - 1 Jun 2011

Besse B, Zalcman G

Abstract excerpt

The arrival of tyrosine kinase inhibitors (TKI) in first line of treatment for advanced non-small cell lung cancer with EGFR mutations has changed the strategy of treatment of theses patients. Indeed, response rates in these cases reach around 60 to 70%, with a progression-free survival greatly prolonged, up to 10 months. It seems that these patients with mutated tumor benefit from TKI whatever the treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crizotinib
Share to Drug Administration Schedule
Share to Evidence-Based Medicine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gefitinib

Share to Genes, erbB-1

Share to Pyrazoles

Share to Pyridines

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 21777763
DOI: 10.1016/S0761-8417(11)70007-4

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[What is the best sequence of treatment for patients with EGFR mutations?].PMID 21777763Read ↗

Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC.Semantic proximity Read ↗

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma.Semantic proximity Read ↗

[Treatment of advanced NSCLC with unknown EGFR gene status --TKI or chemotherapy?].Semantic proximity Read ↗

[Treatment choice after EGFR-TKI resistance].Semantic proximity Read ↗

[Should we always use EGFR mutation analysis prior to palliative firstline therapy of metastatic adenocarcinoma of the lung? Pro].Semantic proximity Read ↗

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.Semantic proximity Read ↗

Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed?Semantic proximity Read ↗

[Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC].Semantic proximity Read ↗

[Detection and evaluation of EGFR mutation status in serum of patients with advanced non-small cell lung cancer treated with EGFR-TKIs].Semantic proximity Read ↗

[Should we always use EGFR mutation analysis prior to palliative firstline therapy of metastatic adenocarcinoma of the lung? Contra].Semantic proximity Read ↗

Switch to EGFR-TKI after upfront platinum doublet induction therapy in non-small cell lung cancer (NSCLC) patients with EGFR (Epidermal Growth Factor Receptor) mutation: A multicentre retrospective study.Semantic proximity Read ↗

[Epidermal growth factor receptor (EGFR): therapeutic target in the treatment of lung adenocarcinoma].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.